Antimicrobial susceptibility of vancomycin-resistant entorococcus faecium: Potential utility of fosfomycin

Scandinavian Journal of Infectious Diseases

Volumn 35, Issue 1, 2003, Pages 12-14

  Shrestha, Nabin K ^a   Chua, Jimmy D ^a   Tuohy, Marion J ^a   Wilson, Deborah A ^a   Procop, Gary W ^a   Longworth, David L ^a   Isada, Carlos M ^a   Hall, Gerri S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; FOSFOMYCIN; LINEZOLID; NITROFURANTOIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; BLOOD SAMPLING; CONTROLLED STUDY; DEVICE; DRUG USE; ENTEROCOCCUS FAECIUM; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OBSERVER VARIATION; PREVALENCE; URINALYSIS; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BLOOD; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECIUM; FEMALE; FOSFOMYCIN; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; SENSITIVITY AND SPECIFICITY; URINE; VANCOMYCIN RESISTANCE;

EID: 0344406075     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/0036554021000026985     Document Type: Article

References (14)

1. Moellering RC Jr. Enterococcus species, Streptococcus bovis, and Leuconostoc species. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and practice of infectious diseases, 4th edn. New York: Churchill Livingstone; 2000. pp. 2147-56.
2. Fuchs PC, Barry AL, Brown SD. Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centers by three methods. J Antimicrob Chemother 1999; 43: 137-40.
3. Shrestha NK, Amud DA, Riebel JW, Goldman MP, Tomford JW. Treatment of a complicated vancomycin-resistant enterococcal urinary tract infection with fosfomycin. Infect Dis Clin Pract 2000; 9: 368-71.
4. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: Tenth International Supplement. Wayne, PA: National Committee for Clinical Laboratory Standards; 2000. M100-10.
5. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: Twelfth International Supplement. Wayne, PA: National Committee for Clinical Laboratory Standards; 2002. M100-12.
6. Perri MB, Hershberger E, Ionescu M, Lauter C, Zervos MJ. In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin. Diagn Microbiol Infect Dis 2002; 42: 269-71.
7. Allerberger F, Klare I. In-vitro susceptibility of fosfomycin against vancomycin-resistant enterococci. J Antimicrob Chemother 1999; 43: 211-7.
8. Andrews JM, Baquero F, Beltran JM, Canton E, Crokaert F, Gobernado M, et al. International collaborative study on standardization of bacterial sensitivity to fosfomycin. J Antimicrob Chemother 1983; 12: 357-61.
9. Clemett D, Markham A. Linezolid. Drugs 2000; 59: 815-27, Discussion 828.
10. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000; 342: 710-21.
11. Low DE, Keller N, Barth A, Jones RN. Clinical prevalence, antimicrobial susceptibility and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program 1997-1999. Clin Infect Dis 2001; 32 (Suppl 2): S133-45.
12. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001; 357: 1179.
13. 2002 Drug topics red book. Montvale, NJ: Thomson Medical Economics; 2002. pp. 441, 551, 600.
14. Shrestha NK, Tomford JW. Fosfomycin: a review. Infect Dis Clin Pract 2001; 10: 255-60.